Beta-sitosterol is one of the main dietary phytosterols found in plants which have a similar skeleton as cholesterol. In human clinical trials, beta-sitosterol has been shown to have cholesterol-lowering effects and to relieve symptoms of benign prostatic hyperplasia. There has been a large amount of basic research conducted for potential applications of beta-sitosterol in a diverse range of conditions including cervical cancer, breast cancer, cystic fibrosis, and others. Beta-sitosterol is available over the counter as a natural health supplement and is marketed for a wide range of applications including headaches, tuberculosis, allergies, cancers, fibromyalgia, lupus, asthma, hair loss and many others.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: P42574 Gene ID: 836.0 Gene Symbol: CASP3 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/12579296 |
|||
Target ID: P17252 Gene ID: 5578.0 Gene Symbol: PRKCA Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/28553226 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | Unknown Approved UseUnknown |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Effect of β-sitosterol on the expression of HPV E6 and p53 in cervical carcinoma cells. | 2015 |
|
| Dietary supplements for benign prostatic hyperplasia: an overview of systematic reviews. | 2012-11 |
|
| Beta-sitosterol, a plant sterol, induces apoptosis and activates key caspases in MDA-MB-231 human breast cancer cells. | 2003-02-13 |
|
| Beta-sitosterols for benign prostatic hyperplasia. | 2000 |
|
| The influence of beta-sitosterol on biliary cholesterol saturation and bile acid kinetics in man. | 1978 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/345413
Over 6 to 8 weeks beta-sitosterol supplementation of 12 g/day resulted in an average of 11% decrease in serum cholesterol and a 12% decrease in biliary cholesterol saturation.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26199569
Human cervical cancer cell lines, Caski and HeLa, were cultured in RPMI-1640 and supplemented with 10% foetal bovine serum and incubated at 37 deg-c in an atmosphere with 5% CO2. Cells were treated with 20 umol/L of beta-sitosterol for 48 hours and examined for changes by light microscopy, electron microscopy, and transmission electron microscopy. Changes in mRNA and protein expression were quantified using Real-Time qPCR and western blots. The treatment with beta-sitosterol reduced expression of PCNA, increased p53 mRNA, decreased the amount of HPV E6 transcripts. Cells treated with beta-sitosterol also exhibited loss of cell surface microvilli and increased electron density in the cell membrane.
| Substance Class |
Mixture
Created
by
admin
on
Edited
Mon Mar 31 18:38:30 GMT 2025
by
admin
on
Mon Mar 31 18:38:30 GMT 2025
|
| Record UNII |
G7V636VTDY
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
DSLD |
2794 (Number of products:1)
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
G7V636VTDY
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
27693
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
SUB15255MIG
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
Sitosterol
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
CHEMBL2108117
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
G7V636VTDY
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
D012855
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
9808
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | RxNorm | ||
|
12002-39-0
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
2451
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
100000078095
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY | |||
|
DTXSID401025687
Created by
admin on Mon Mar 31 18:38:30 GMT 2025 , Edited by admin on Mon Mar 31 18:38:30 GMT 2025
|
PRIMARY |
Any of these components may be present:
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |